NCT02614300

Brief Summary

Pulmonary rehabilitation programs are part of the multidisciplinary treatment of some chronic respiratory diseases such as COPD (chronic obstructive pulmonary disease). Although clinical guidelines of other diseases such as non-cystic fibrosis bronchiectasis (nCFBE) discuss the benefits of these programs in quality of life and exercise tolerance, evidence of such intervention in nCFBE patients is insufficient. Longer studies are needed with larger sample sizes and optimized to maximize the response and maintain long-term benefits. The present study aims to examine the effects in exercise tolerance of a pulmonary rehabilitation program combined with respiratory physiotherapy in patients with nCFBE. It is a randomized controlled clinical trial with a total duration of 24 months. The intervention will be performed during 12 weeks and then will be a period of 12 months of maintenance. This is a multicenter study involving the following Hospitals: Hospital Clinic, Hospital la Plató and Hospital del Mar of Barcelona, Hospital Josep Trueta of Girona, Royal Infirmary of Edinburgh and Fondazione Maugeri di Lumezzane of Italy. Subjects will be randomized into three groups in a ratio (1: 1: 1) (1) Pulmonary Rehabilitation (2) Chest Physiotherapy and (3) Pulmonary Rehabilitation + Chest Physiotherapy. Hospital la Plató from Barcelona will be responsible for carrying out the Control Group. The primary endpoint will be the test of "endurance shuttle walk test".

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

November 18, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 25, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Last Updated

November 25, 2015

Status Verified

November 1, 2015

Enrollment Period

2.1 years

First QC Date

November 18, 2015

Last Update Submit

November 23, 2015

Conditions

Keywords

pulmonary rehabilitationchest physiotherapynon-cystic fibrosis bronchiectasisexercise tolerancebronchiectasisrespiratory therapy

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline Exercise tolerance capacity measured as the distance walked in meters during the shuttle test at constant speed (ESWT) at 12 weeks.

    At Screening and 12 weeks of intervention

Secondary Outcomes (7)

  • Exacerbations incidence and symptoms

    During all study (12 weeks of intervention)

  • Change from Baseline Health related quality of life at 12 weeks.

    At Screening and 12 weeks of intervention with Quality of Life Questionnaire (QoL-B)

  • Change from Baseline Impact of expectoration on the quality of life at 12 weeks.

    At Screening and 12 weeks of intervention with Leicester Cough Questionnaire (LCQ)

  • Sputum colour

    During all study (12 weeks of intervention) with Murray's colour scale

  • Change from Baseline FEV1, FVC and FEV1/FVC at 12 weeks.

    At Screening and 12 weeks of intervention with Pulmonary Function Tests

  • +2 more secondary outcomes

Study Arms (4)

Pulmonary Rehabilitation

ACTIVE COMPARATOR

These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.

Other: Pulmonary Rehabilitation

Chest Physiotherapy

ACTIVE COMPARATOR

The ELTGOL technique ("total slow expiration with glottis open in lateral decubitus") for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary.

Other: Chest Physiotherapy

Pulmonary Rehabilitation and Chest Physiotherapy

ACTIVE COMPARATOR

This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale. Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs.

Other: Pulmonary Rehabilitation and Chest Physiotherapy

Control Group

NO INTERVENTION

For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist. The physiotherapist will also do monthly telephone calls for patient's monitoring.

Interventions

The patient will come 3 times per week during 12 weeks Each session 1h15min

Pulmonary Rehabilitation and Chest Physiotherapy

The patient will come 3 times per week during 12 weeks Each session 45min

Pulmonary Rehabilitation

The patient will come 3 times per week during 12 weeks Each session 30min

Chest Physiotherapy

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged between 50-80 years;
  • No performing regular physiotherapy treatment or physical training (≤ 1 time/week);
  • Stable disease \[no changes in the chronic therapy (both inhaled and systematic) in the usual respiratory symptoms (according to the medical evaluation) and spirometry in the last 4 weeks prior to study recruitment\];
  • Regular cough and expectoration;
  • Ability to follow the exercise program;
  • Ability to perform all clinical tests, to understand the process and the purposes of the study;
  • A history of at least 2 exacerbations during the previous year requiring antibiotic treatment and;
  • Signed informed consent.

You may not qualify if:

  • Active smokers, ex-smokers of less than 1 year prior to recruitment and/or a history of \>20 smoking packs/year;
  • FEV1 \<30% or/and TLC\<40% ;
  • Diagnosis of cystic fibrosis, sarcoidosis, pulmonary fibrosis, active tuberculosis or non tuberculosis mycobacterial infection,
  • Diagnosis of asthma or COPD as a primary respiratory disease and associated secondary bronchiectasis,
  • Patients with unstable cardiac disease or locomotor difficulties that preclude exercise (eg, severe arthritis or severe peripheral vascular disease);
  • Chronic respiratory failure and/or oxygen therapy;
  • Frequent haemoptysis (≥ 2 times/month);
  • Any physical and psychological disorder that interferes with protocol compliance;
  • Participation in a clinical trial implying any change in usual pharmacological treatment in the last 6 months before recruitment;
  • Being on the waiting list for lung transplantation or have been transplanted.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Herrero-Cortina B, Alcaraz-Serrano V, Torres A, Polverino E. Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. Respir Care. 2020 Oct;65(10):1478-1487. doi: 10.4187/respcare.07175. Epub 2020 Feb 18.

MeSH Terms

Conditions

Bronchiectasis

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract Diseases

Central Study Contacts

Victoria Alcaraz, Physiotherapist

CONTACT

Eva Polverino, Medical Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist in Respiratory Diseases

Study Record Dates

First Submitted

November 18, 2015

First Posted

November 25, 2015

Study Start

November 1, 2015

Primary Completion

December 1, 2017

Last Updated

November 25, 2015

Record last verified: 2015-11